Drug Interactions between famotidine and Viberzi
This report displays the potential drug interactions for the following 2 drugs:
- famotidine
- Viberzi (eluxadoline)
Interactions between your drugs
No interactions were found between famotidine and Viberzi. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
famotidine
A total of 314 drugs are known to interact with famotidine.
- Famotidine is in the drug class H2 antagonists.
-
Famotidine is used to treat the following conditions:
- Allergic Urticaria (off-label)
- Cutaneous Mastocytosis
- Duodenal Ulcer
- Duodenal Ulcer Prophylaxis
- Erosive Esophagitis
- GERD
- Hiatal Hernia (off-label)
- Indigestion
- Laryngopharyngeal Reflux (off-label)
- Pathological Hypersecretory Conditions
- Peptic Ulcer
- Stomach Ulcer
- Upper GI Hemorrhage
- Urticaria (off-label)
- Zollinger-Ellison Syndrome
Viberzi
A total of 214 drugs are known to interact with Viberzi.
- Viberzi is in the drug class peripheral opioid receptor mixed agonists/antagonists.
- Viberzi is used to treat the following conditions:
Drug and food interactions
eluxadoline food
Applies to: Viberzi (eluxadoline)
CONTRAINDICATED: Consumption of more than 3 alcoholic beverages per day may increase the risk of acute pancreatitis during treatment with eluxadoline. Pancreatitis has been reported rarely during clinical trials of eluxadoline, and may or may not be related to sphincter of Oddi spasm.
ADJUST DOSING INTERVAL: High-fat meals may reduce the oral bioavailability of eluxadoline. In 28 healthy volunteers, administration of a single 100 mg dose of eluxadoline with a high-fat meal (approximately 800 to 1000 total calories, 50% from fat) decreased eluxadoline peak plasma concentration (Cmax) and systemic exposure (AUC) by 50% and 60%, respectively, compared to administration in the fasted state. There was no significant effect on the time to peak concentration (Tmax). The clinical relevance of this interaction is unknown. It should be noted that phase 3 clinical trials were conducted under fed conditions.
MANAGEMENT: Chronic or acute excessive use of alcohol should be avoided during treatment with eluxadoline. Alcoholism, alcohol abuse, alcohol addiction, and consumption of more than 3 alcoholic beverages per day are considered contraindications to the use of eluxadoline. The product labeling recommends taking eluxadoline with food. Patients should be advised to stop taking eluxadoline and seek medical attention if they experience potential symptoms of pancreatitis such as persistent nausea, vomiting, abdominal tenderness, and upper abdominal pain, especially that which is made worse after eating or radiates to the back or shoulders.
References (1)
- (2015) "Product Information. Viberzi (eluxadoline)." Actavis Pharma, Inc.
famotidine food
Applies to: famotidine
H2 antagonists may reduce the clearance of nicotine. Cimetidine, 600 mg given twice a day for two days, reduced clearance of an intravenous nicotine dose by 30%. Ranitidine, 300 mg given twice a day for two days, reduced clearance by 10%. The clinical significance of this interaction is not known. Patients should be monitored for increased nicotine effects when using the patches or gum for smoking cessation and dosage adjustments should be made as appropriate.
References (1)
- Bendayan R, Sullivan JT, Shaw C, Frecker RC, Sellers EM (1990) "Effect of cimetidine and ranitidine on the hepatic and renal elimination of nicotine in humans." Eur J Clin Pharmacol, 38, p. 165-9
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.